1. Home
  2. MERC vs IMRN Comparison

MERC vs IMRN Comparison

Compare MERC & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

N/A

Current Price

$0.25

Market Cap

8.5M

ML Signal

N/A

Logo Immuron Limited

IMRN

Immuron Limited

N/A

Current Price

$0.82

Market Cap

7.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MERC
IMRN
Founded
1968
1994
Country
Canada
Australia
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
7.7M
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
MERC
IMRN
Price
$0.25
$0.82
Analyst Decision
Sell
Analyst Count
2
0
Target Price
★ $0.13
N/A
AVG Volume (30 Days)
★ 25.4M
16.7K
Earning Date
11-05-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $1,169,145,000.00
N/A
Revenue This Year
$0.85
$16.39
Revenue Next Year
$11.46
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 25.50
N/A
52 Week Low
$0.12
$0.68
52 Week High
$2.85
$1.99

Technical Indicators

Market Signals
Indicator
MERC
IMRN
Relative Strength Index (RSI) 56.93 33.29
Support Level $0.14 $0.73
Resistance Level $0.41 $0.89
Average True Range (ATR) 0.04 0.07
MACD 0.02 -0.00
Stochastic Oscillator 52.79 27.32

Price Performance

Historical Comparison
MERC
IMRN

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.

About IMRN Immuron Limited

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Share on Social Networks: